CTLA4 and neoplasm: The 1E5 model had a small yet significant decrease in total tumor burden with the anti-CTLA-4 monotherapy at day 14, but did not translate to an increase in overall survival; however, the combination of anti-CTLA-4 plus anti-PD-L1 induced a reduction of tumor burden at 14 days that led to improved overall survival (Fig. 6b, Supl.